Literature DB >> 31313076

Severe Consequences of SAC3/FIG4 Phosphatase Deficiency to Phosphoinositides in Patients with Charcot-Marie-Tooth Disease Type-4J.

Assia Shisheva1, Diego Sbrissa2, Bo Hu3, Jun Li3,4.   

Abstract

Charcot-Marie-Tooth disease type-4J (CMT4J), an autosomal recessively inherited peripheral neuropathy characterized by neuronal degeneration, segmental demyelination, and limb muscle weakness, is caused by compound heterozygous mutations in the SAC3/FIG4 gene, resulting in SAC3/FIG4 protein deficiency. SAC3/FIG4 is a phosphatase that not only turns over PtdIns(3,5)P2 to PtdIns3P but also promotes PtdIns(3,5)P2 synthesis by activating the PIKFYVE kinase that also makes PtdIns5P. Whether CMT4J patients have alterations in PtdIns(3,5)P2PtdIns5P or in other phosphoinositides (PIs), and if yes, in what direction these changes might be, has never been examined. We performed PI profiling in primary fibroblasts from a cohort of CMT4J patients. Subsequent to myo-[2-3H]inositol cell labeling to equilibrium, steady-state levels of PIs were quantified by HPLC under conditions concurrently detecting PtdIns5P, PtdIns(3,5)P2, and the other PIs. Immunoblotting verified SAC3/FIG4 depletion in CMT4J fibroblasts. Compared to normal human controls (n = 9), both PtdIns(3,5)P2 and PtdIns5P levels were significantly decreased in CMT4J fibroblasts (n = 13) by 36.4 ± 3.6% and 43.1 ± 4.4%, respectively (p < 0.0001). These reductions were independent of patients' gender or disease onset. Although mean values for PtdIns3P in the CMT4J cohort remained unchanged, there were high variations in PtdIns3P among individual patients. Aberrant endolysosomal vacuoles, typically seen under PtdIns(3,5)P2 reduction, were apparent but not in fibroblasts from all patients. The subset of patients without aberrant vacuoles exhibited especially low PtdIns3P levels. Concomitant decreases in PtdIns5P and PtdIns(3,5)P2 and the link between PtdIns3P levels and cellular vacuolization are novel insights shedding further light into the molecular determinants in CMT4J polyneuropathy.

Entities:  

Keywords:  Charcot-Marie-Tooth type-4J polyneuropathy; Demyelination; HPLC; PAS complex; PIKFYVE; Phosphoinositides; PtdIns3P/PtdIns5P/PtdIns(3,5)P2; SAC3/FIG4

Mesh:

Substances:

Year:  2019        PMID: 31313076     DOI: 10.1007/s12035-019-01693-8

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  66 in total

1.  ALS-associated protein FIG4 is localized in Pick and Lewy bodies, and also neuronal nuclear inclusions, in polyglutamine and intranuclear inclusion body diseases.

Authors:  Tomoya Kon; Fumiaki Mori; Kunikazu Tanji; Yasuo Miki; Yasuko Toyoshima; Mari Yoshida; Hidenao Sasaki; Akiyoshi Kakita; Hitoshi Takahashi; Koichi Wakabayashi
Journal:  Neuropathology       Date:  2013-07-29       Impact factor: 1.906

2.  TOM1 is a PI5P effector involved in the regulation of endosomal maturation.

Authors:  Frédéric Boal; Rana Mansour; Marion Gayral; Estelle Saland; Gaëtan Chicanne; Jean-Marie Xuereb; Marlène Marcellin; Odile Burlet-Schiltz; Philippe J Sansonetti; Bernard Payrastre; Hélène Tronchère
Journal:  J Cell Sci       Date:  2015-01-14       Impact factor: 5.285

3.  Plentiful PtdIns5P from scanty PtdIns(3,5)P2 or from ample PtdIns? PIKfyve-dependent models: Evidence and speculation (response to: DOI 10.1002/bies.201300012).

Authors:  Assia Shisheva; Diego Sbrissa; Ognian Ikonomov
Journal:  Bioessays       Date:  2014-11-18       Impact factor: 4.345

Review 4.  Inositol lipids: from an archaeal origin to phosphatidylinositol 3,5-bisphosphate faults in human disease.

Authors:  Robert H Michell
Journal:  FEBS J       Date:  2013-09-03       Impact factor: 5.542

5.  The Fab1/PIKfyve phosphoinositide phosphate kinase is not necessary to maintain the pH of lysosomes and of the yeast vacuole.

Authors:  Cheuk Y Ho; Christopher H Choy; Christina A Wattson; Danielle E Johnson; Roberto J Botelho
Journal:  J Biol Chem       Date:  2015-02-20       Impact factor: 5.157

6.  Class III PI 3-kinase is the main source of PtdIns3P substrate and membrane recruitment signal for PIKfyve constitutive function in podocyte endomembrane homeostasis.

Authors:  Ognian C Ikonomov; Diego Sbrissa; Madhusudan Venkatareddy; Ellen Tisdale; Puneet Garg; Assia Shisheva
Journal:  Biochim Biophys Acta       Date:  2015-01-22

7.  ArPIKfyve homomeric and heteromeric interactions scaffold PIKfyve and Sac3 in a complex to promote PIKfyve activity and functionality.

Authors:  Diego Sbrissa; Ognian C Ikonomov; Homer Fenner; Assia Shisheva
Journal:  J Mol Biol       Date:  2008-10-11       Impact factor: 5.469

8.  Role for a novel signaling intermediate, phosphatidylinositol 5-phosphate, in insulin-regulated F-actin stress fiber breakdown and GLUT4 translocation.

Authors:  Diego Sbrissa; Ognian C Ikonomov; Jana Strakova; Assia Shisheva
Journal:  Endocrinology       Date:  2004-07-29       Impact factor: 4.736

9.  Vacuole size control: regulation of PtdIns(3,5)P2 levels by the vacuole-associated Vac14-Fig4 complex, a PtdIns(3,5)P2-specific phosphatase.

Authors:  Simon A Rudge; Deborah M Anderson; Scott D Emr
Journal:  Mol Biol Cell       Date:  2003-10-03       Impact factor: 4.138

10.  Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth disease CMT4J.

Authors:  Guy M Lenk; Cole J Ferguson; Clement Y Chow; Natsuko Jin; Julie M Jones; Adrienne E Grant; Sergey N Zolov; Jesse J Winters; Roman J Giger; James J Dowling; Lois S Weisman; Miriam H Meisler
Journal:  PLoS Genet       Date:  2011-06-02       Impact factor: 5.917

View more
  2 in total

1.  Insights into Lysosomal PI(3,5)P2 Homeostasis from a Structural-Biochemical Analysis of the PIKfyve Lipid Kinase Complex.

Authors:  Joshua A Lees; PeiQi Li; Nikit Kumar; Lois S Weisman; Karin M Reinisch
Journal:  Mol Cell       Date:  2020-10-23       Impact factor: 17.970

2.  Adeno-associated virus gene therapy to the rescue for Charcot-Marie-Tooth disease type 4J.

Authors:  John Svaren
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 19.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.